Scrip
Roche and Biogen Idec discontinue ocrelizumab for RA
20 May 2010
Katie McQue
Please Login to read the full article.
20 May 2010
Katie McQue
katie.mcque@informa.com
Roche and Biogen Idec have discontinued the Phase III development of their humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) after deciding it has an unfavourable risk:benefit profile.
The news follows the suspension of the drug's RA programme in March after...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Roche and Biogen Idec halt ocrelizumab RA development on infection data and deaths
- Roche and Biogen Idec's ocrelizumab positive in first Phase III trial for RA
- Roche and Biogen Idec's ocrelizumab looks positive in Phase II for RRMS
- Genentech/Biogen Idec's Rituxan denied approval for earlier RA use
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
